3Chopt Investment Partners LLC Sells 14,322 Shares of Bristol Myers Squibb Company $BMY

3Chopt Investment Partners LLC lowered its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 54.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,138 shares of the biopharmaceutical company’s stock after selling 14,322 shares during the quarter. 3Chopt Investment Partners LLC’s holdings in Bristol Myers Squibb were worth $655,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $25,000. Physician Wealth Advisors Inc. lifted its holdings in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 202 shares during the last quarter. EQ Wealth Advisors LLC purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at $32,000. KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Bristol Myers Squibb during the 3rd quarter valued at $35,000. Finally, Garner Asset Management Corp purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at $35,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $54.80 on Tuesday. The stock has a 50-day simple moving average of $58.25 and a two-hundred day simple moving average of $56.37. The firm has a market capitalization of $111.91 billion, a P/E ratio of 15.39, a PEG ratio of 0.16 and a beta of 0.24. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the business posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Cantor Fitzgerald increased their price objective on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, April 8th. Morgan Stanley reiterated an “underweight” rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Piper Sandler reiterated an “overweight” rating and set a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Sunday, April 19th. Finally, Bank of America decreased their price objective on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, April 9th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.